Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

619 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
NT-proBNP by Itself Predicts Death and Cardiovascular Events in High-Risk Patients With Type 2 Diabetes Mellitus.
Malachias MVB, Jhund PS, Claggett BL, Wijkman MO, Bentley-Lewis R, Chaturvedi N, Desai AS, Haffner SM, Parving HH, Prescott MF, Solomon SD, De Zeeuw D, McMurray JJV, Pfeffer MA. Malachias MVB, et al. Among authors: haffner sm. J Am Heart Assoc. 2020 Oct 20;9(19):e017462. doi: 10.1161/JAHA.120.017462. Epub 2020 Sep 23. J Am Heart Assoc. 2020. PMID: 32964800 Free PMC article. Clinical Trial.
Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial.
Califf RM, Boolell M, Haffner SM, Bethel M, McMurray J, Duggal A, Holman RR; NAVIGATOR Study Group. Califf RM, et al. Among authors: haffner sm. Am Heart J. 2008 Oct;156(4):623-32. doi: 10.1016/j.ahj.2008.05.017. Am Heart J. 2008. PMID: 18946890 Clinical Trial.
Dual renin-angiotensin system blockade and kidney disease.
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Pfeffer MA. Parving HH, et al. Among authors: haffner sm. J Am Coll Cardiol. 2009 Jul 14;54(3):278-9; author reply 279-80. doi: 10.1016/j.jacc.2009.02.074. J Am Coll Cardiol. 2009. PMID: 19589445 Free article. No abstract available.
Baseline characteristics in the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE).
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Nicolaides M, Richard A, Xiang Z, Armbrecht J, Pfeffer MA; ALTITUDE Investigators. Parving HH, et al. Among authors: haffner sm. J Renin Angiotensin Aldosterone Syst. 2012 Sep;13(3):387-93. doi: 10.1177/1470320311434818. Epub 2012 Feb 14. J Renin Angiotensin Aldosterone Syst. 2012. PMID: 22333485 Free article. Clinical Trial.
Prediabetes and the risk of diabetes.
McMurray JJ, Haffner SM, Califf RM, Holman RR. McMurray JJ, et al. Among authors: haffner sm. Lancet. 2012 Oct 6;380(9849):1225-6; author reply 1226. doi: 10.1016/S0140-6736(12)61706-1. Lancet. 2012. PMID: 23040850 No abstract available.
Cardiorenal end points in a trial of aliskiren for type 2 diabetes.
Parving HH, Brenner BM, McMurray JJ, de Zeeuw D, Haffner SM, Solomon SD, Chaturvedi N, Persson F, Desai AS, Nicolaides M, Richard A, Xiang Z, Brunel P, Pfeffer MA; ALTITUDE Investigators. Parving HH, et al. Among authors: haffner sm. N Engl J Med. 2012 Dec 6;367(23):2204-13. doi: 10.1056/NEJMoa1208799. Epub 2012 Nov 3. N Engl J Med. 2012. PMID: 23121378 Free article. Clinical Trial.
Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.
Preiss D, Thomas LE, Sun JL, Haffner SM, Holman RR, Standl E, Leiter LA, Mazzone T, Rutten GE, Tognoni G, Martinez FA, Chiang FT, Califf RM, McMurray JJ. Preiss D, et al. Among authors: haffner sm. BMJ Open. 2012 Nov 30;2(6):e001925. doi: 10.1136/bmjopen-2012-001925. Print 2012. BMJ Open. 2012. PMID: 23204139 Free PMC article.
619 results